Table 2.
Patient’s demographic, clinical, systemic, and local therapy information at diagnosis of brain metastasis stratified by subtype
| Type | HER2-/HR+ (%) | HER2+/HR+ (%) | HER2+/HR- (%) | Triple Negative (%) |
|---|---|---|---|---|
| Age | ||||
| <40 years | 9 (9) | 5 (10) | 10 (16) | 12 (12) |
| 40–49 years | 32 (32) | 19 (37) | 17 (27) | 30 (29) |
| 50–59 years | 33 (33) | 15 (29) | 22 (35) | 35 (35) |
| 60–69 years | 19 (19) | 10 (20) | 10 (16) | 17 (17) |
| >70 years | 7 (7) | 2 (4) | 4 (6) | 7 (7) |
| Local Control | ||||
| Yes | 87 (87) | 44 (86) | 54 (86) | 83 (82) |
| No | 13 (13) | 7 (14) | 9 (14) | 18 (18) |
| KPS | ||||
| <70 | 3 (3) | 6 (12) | 4 (6) | 9 (9) |
| >70 | 97 (97) | 45 (88) | 59 (94) | 92 (91) |
| Number of Brain Metastasis | ||||
| 1 | 53 (53) | 22 (43) | 30 (48) | 54 (54) |
| 2–3 | 38 (38) | 22 (43) | 24 (38) | 35 (35) |
| >3 | 9 (9) | 7 (14) | 9 (14) | 12 (12) |
| Number of Extracranial Metastasis | ||||
| 0 | 19 (19) | 5 (10) | 15 (24) | 15 (15) |
| 1 | 23 (23) | 10 (20) | 16 (25) | 42 (41) |
| 2 | 32 (32) | 22 (43) | 23 (37) | 28 (28) |
| >3 | 26 (26) | 14 (27) | 9 (14) | 16 (16) |
| Brain Metastasis Treatment | ||||
| Surgery | 19 (19) | 5 (10) | 12 (19) | 19 (19) |
| SRS | 43 (43) | 23 (45) | 21 (33) | 45 (45) |
| WBRT + Surgery | 26 (26) | 16 (31) | 25 (40) | 29 (28) |
| SRS + Surgery | 7 (7) | 3 (6) | 1 (2) | 6 (6) |
| SRS + WBRT | 5 (5) | 4 (8) | 4 (6) | 2 (2) |
| Anti-HER2 Treatment | ||||
| Yes | 2 (2) | 45 (88) | 54 (86) | 2 (2) |
| No | 98 (98) | 6 (12) | 9 (14) | 99 (98) |
| Hormonal Therapy | ||||
| Yes | 84 (84) | 47 (92) | 2 (3) | 2 (2) |
| No | 16 (16) | 4 (8) | 61 (97) | 99 (98) |